Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Bicycle Therapeutics plc

Market Cap 279M 244M 225M 211M 395M 26.34B 398M 2.67B 1.04B 12.96B 1.05B 1.03B 45.04B P/E 2026 *
-1.72x
P/E 2027 * -1.9x
Enterprise Value -233M -203M -187M -176M -329M -21.95B -332M -2.23B -864M -10.8B -874M -855M -37.54B EV / Sales 2026 *
-12.8x
EV / Sales 2027 * -8.85x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day-0.99%
1 week-0.74%
Current month-14.71%
1 month-10.11%
3 months-21.10%
6 months-42.45%
Current year-43.50%
1 week 3.95
Extreme 3.95
4.24
1 month 3.95
Extreme 3.95
4.74
Current year 3.95
Extreme 3.95
7.34
1 year 3.95
Extreme 3.95
9.18
3 years 3.95
Extreme 3.95
28.91
5 years 3.95
Extreme 3.95
62.08
10 years 3.95
Extreme 3.95
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 75 01/01/2009
Director/Board Member 57 01/09/2015
Director/Board Member 69 18/07/2019
Date Insider Type Main position Quantity % Market Cap.
04-02Sell

Chief Technology Officer

2,404 0.0063%
04-02Sell

Chief Financial Officer

901 0.0024%
04-02Sell

Chief Operating Officer

1,408 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
-0.99%-0.74%-47.64%-85.32% 282M
-2.23%-0.03%+61.34%+109.10% 56.24B
+4.60%+5.85%+54.47%+43.04% 43.76B
-1.44%+5.50%-13.41%-19.24% 23.32B
-2.69%+4.27%-4.47%+379.00% 21.34B
+3.22%+3.77%+19.92%-35.05% 15.75B
-0.67%+1.18%+12.91%-39.22% 15.6B
-1.01%-1.27%+25.52%+171.92% 13.18B
+3.07%+3.59%+25.54% - 12.01B
+4.95%+7.51%+123.21%+249.05% 11.87B
Average +0.68%+3.41%+25.74%+85.92% 21.34B
Weighted average by Cap. +0.50%+3.54%+37.65%+97.81%

Financials

2026 *2027 *
Net sales 18.24M 15.91M 14.67M 13.81M 25.77M 1.72B 25.99M 175M 67.67M 846M 68.44M 66.97M 2.94B 14.11M 12.31M 11.35M 10.69M 19.95M 1.33B 20.11M 135M 52.37M 655M 52.97M 51.83M 2.28B
Net income -154M -134M -124M -116M -217M -14.49B -219M -1.47B -570M -7.13B -577M -564M -24.78B -162M -142M -131M -123M -229M -15.31B -231M -1.55B -602M -7.53B -609M -596M -26.18B
Net Debt -512M -447M -412M -388M -724M -48.29B -730M -4.9B -1.9B -23.76B -1.92B -1.88B -82.58B -404M -353M -325M -306M -571M -38.12B -576M -3.87B -1.5B -18.76B -1.52B -1.48B -65.19B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
18/06/26 4.000 $ -0.99% 317,558
17/06/26 4.040 $ +0.50% 969,140
16/06/26 4.020 $ -3.13% 947,788
15/06/26 4.150 $ +2.47% 2,982,352
12/06/26 4.050 $ -1.22% 767,609
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.000USD
Average target price
12.62USD
Spread / Average Target
+215.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!